Zhitong Finance App News, Shiyao Group (01093.HK) announced that SYH2056 tablets (this product) developed by the Group are intended to treat depression. A phase I clinical trial (Research Plan No.: SYH2056-001) to evaluate the safety, tolerability and pharmacokinetic characteristics of a single oral administration of this product in Chinese health participants and food effects studies has been officially launched in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.